Spectral AI, Inc. (NASDAQ:MDAI – Free Report) – Northland Securities boosted their FY2027 earnings per share estimates for Spectral AI in a research note issued on Tuesday, October 27th. Northland Securities analyst L. Horton now expects that the company will post earnings of ($0.34) per share for the year, up from their prior forecast of ($0.44). Northland Securities currently has a “Strong-Buy” rating on the stock. The consensus estimate for Spectral AI’s current full-year earnings is ($0.50) per share.
Spectral AI (NASDAQ:MDAI – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. The firm had revenue of $3.52 million during the quarter, compared to analysts’ expectations of $4.17 million.
MDAI has been the subject of several other reports. Wall Street Zen upgraded shares of Spectral AI from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings upgraded shares of Spectral AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $4.00.
Read Our Latest Stock Analysis on MDAI
Spectral AI Trading Up 2.0%
Shares of NASDAQ:MDAI opened at $1.56 on Thursday. Spectral AI has a twelve month low of $1.18 and a twelve month high of $2.97. The company has a market cap of $50.22 million, a PE ratio of -4.46 and a beta of 1.21. The company’s 50 day moving average is $1.59 and its 200 day moving average is $1.70.
About Spectral AI
Spectral AI, Inc is a medical diagnostic technology company focused on using artificial intelligence and advanced imaging to support earlier, more objective assessment of wound healing. The company develops predictive diagnostic systems intended to help clinicians evaluate wounds and make treatment decisions.
Its principal product is the DeepView System, a noninvasive imaging and artificial intelligence platform designed to assess burn wounds and predict the likelihood that injured tissue will heal without surgical intervention.
Featured Articles
- Five stocks we like better than Spectral AI
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Spectral AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral AI and related companies with MarketBeat.com's FREE daily email newsletter.
